Resistance mechanisms to osimertinib in EGFR-mutated advanced non-small-cell lung cancer: A multicentric retrospective French study

Mehlman Camille; Cadranel Jacques; Rousseau-Bussac Gaelle; Lacave Roger; Pujals Anais; Girard Nicolas; Callens Celine; Gounant Valerie; Theou-Anton Nathalie; Friard Sylvie; Tredaniel Jean; Blons Helene; Dujon Cecile; Duchemann Boris; Schischmanoff Pierre Olivier; Chinet Thierry; Leprieur Etienne Giroux

首页> 外文期刊>Lung cancer: Journal of the International Association for the Study of Lung Cancer >Resistance mechanisms to osimertinib in EGFR-mutated advanced non-small-cell lung cancer: A multicentric retrospective French study

【24h】

Resistance mechanisms to osimertinib in EGFR-mutated advanced non-small-cell lung cancer: A multicentric retrospective French study

机译：EGFR-突变晚期非小细胞肺癌中Osimertinib的抗性机制：多中心回顾性法语研究

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Objectives: The understanding of histo-molecular mechanisms associated with resistance to osimertinib is a critical step to define the optimal treatment strategy in advanced EGFR-mutated Non-Small-Cell-Lung-Cancer (NSCLC).

机译：目的：理解与肺部抗性肌肌抗性相关的组织分子机制是在高级EGFR-突变的非小细胞 - 肺癌（NSCLC）中定义最佳治疗策略的关键步骤。

著录项

来源
《Lung cancer: Journal of the International Association for the Study of Lung Cancer 》 |2019年第2019期| 共8页
作者
Mehlman Camille; Cadranel Jacques; Rousseau-Bussac Gaelle; Lacave Roger; Pujals Anais; Girard Nicolas; Callens Celine; Gounant Valerie; Theou-Anton Nathalie; Friard Sylvie; Tredaniel Jean; Blons Helene; Dujon Cecile; Duchemann Boris; Schischmanoff Pierre Olivier; Chinet Thierry; Leprieur Etienne Giroux;
展开▼
作者单位

Paris Saclay Univ Hop Ambroise Pare APHP Dept Resp Dis &

Thorac Oncol EA 4340 BECCOH UVSQ;

Hop Tenon Grp Hosp HUEP AP HP Chest Dept Thorac Oncol Expert Ctr Paris France;

Creteil Intercommunal Hosp Chest Dept Creteil France;

Sorbonne Univ Paris France;

Henri Mondor Hosp AP HP Dept Pathol Creteil France;

Inst Curie Thorax Inst Paris France;

Inst Curie Dept Genet Paris France;

Univ Hosp Bichat Claude Bernard AP HP Thorac Oncol Dept Paris France;

Univ Hosp Bichat Claude Bernard AP HP Dept Genet Paris France;

Foch Hosp Dept Pneumol Suresnes France;

St Joseph Hosp Dept Pneumol Paris France;

Georges Pompidou European Hosp AP HP Dept Mol Biol Paris France;

Andre Mignot Hosp Dept Pneumol Le Chesnay France;

Avicenne Hosp Dept Oncol AP HP Bobigny France;

Avicenne Hosp AP HP Dept Mol Oncogenet Bobigny France;

Paris Saclay Univ Hop Ambroise Pare APHP Dept Resp Dis &

Thorac Oncol EA 4340 BECCOH UVSQ;

Paris Saclay Univ Hop Ambroise Pare APHP Dept Resp Dis &

Thorac Oncol EA 4340 BECCOH UVSQ;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学 ;
关键词
Non-small cell lung cancer; Osimertinib; EGFR; Resistance; C797S; MET;

机译：非小细胞肺癌;Osimertinib;EGFR;抵抗;C797s;遇见;

相似文献

外文文献
中文文献
专利

1. Resistance mechanisms to osimertinib in EGFR-mutated advanced non-small-cell lung cancer: A multicentric retrospective French study [J] . Mehlman Camille, Cadranel Jacques, Rousseau-Bussac Gaelle, Lung cancer: Journal of the International Association for the Study of Lung Cancer . 2019 ,第期

机译：EGFR-突变晚期非小细胞肺癌中Osimertinib的抗性机制：多中心回顾性法语研究
2. P3.01-037 Understanding Mechanisms of Resistance to Osimertinib by Circulating Tumor DNA Genotyping in Advanced Non-Small-Cell Lung Cancer [J] . Y. Du, W. Zang, G. Wang, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2017 ,第11期

机译：P3.01-037通过在先进的非小细胞肺癌中循环肿瘤DNA基因分型，了解对Osimertinib的抵抗机制
3. Patient-reported outcomes from FLAURA: Osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer [J] . Leighl Natasha B., Karaseva Nina, Nakagawa Kazuhiko, European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2020 ,第1期

机译：患者报告的Flaura的结果：Esimertinib对欧尔替尼或吉替尼患者患有Egfr-突变的晚期非小细胞肺癌的患者
4. Effects of Erlotinib after Acquired Resistance to Gefitinib in Advanced Non-small-cell Lung Cancer [C] . Pan Jingjing, Shi Meiqi, Feng Jifeng Biomedical Engineering and Biotechnology (iCBEB), 2012 International Conference on . 2012

机译：吉非替尼耐药对晚期非小细胞肺癌患者的厄洛替尼治疗效果
5. Pharmacology Profiles of ALK and FLT3 Kinase Inhibitors against Non-Small-Cell Lung Cancer Cells and Acute Myeloid Leukemia Cells with Cancer Driver Mutations [D] . 森政道 2019

机译：ALK和FLT3激酶抑制剂对非小细胞肺癌细胞和急性髓系白血病细胞的癌症驱动突变的药理作用
6. Efficacy of osimertinib for preventing leptomeningeal metastasis derived from advanced EGFR-mutated non-small cell lung cancer: a propensity-matched retrospective study [O] . Xia Wang, Jing Cai, Zhimin Zeng, 2021

机译：Osimertinib用于预防源自高级Egfr-突变的非小细胞肺癌的脑膜炎转移的功效：一种倾向匹配的回顾性研究
7. Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer [O] . Ken Uchibori, Naohiko Inase, Mitsugu Araki, 2017

机译：Brigatinib结合抗EGFR抗体克服了EGFR-突变的非小细胞肺癌中的Osimertinib抗性

Resistance mechanisms to osimertinib in EGFR-mutated advanced non-small-cell lung cancer: A multicentric retrospective French study

摘要

著录项

相似文献

相关主题

期刊订阅